Summary of Tempus AI Q3 2025 Earnings Call

1Key Financial Results and Metrics

Revenue Growth: Tempus reported a strong overall growth of 33% in Genomics, with Oncology growing at 27% and Hereditary testing at 37%.

Adjusted EBITDA: The company achieved positive adjusted EBITDA for the first time, a milestone after 10 years, with a reported figure close to $4 million excluding expenses from the Paige acquisition.

Data Licensing Growth: The Insights business grew by 38%, adding $150 million in total contract value during the quarter.

2Strategic Updates and Business Highlights

Genomics Performance: The growth in Genomics was attributed to an efficient sales force and improved technology integration, allowing for comprehensive results delivery to physicians.

MRD Testing: The company is on track with MRD reimbursement and plans to submit its liquid biopsy xF for regulatory approval by the end of 2025.

Acquisition of Paige: The integration of Paige is expected to enhance Tempus's capabilities in digital pathology and genomic diagnostics, particularly in improving sequencing outcomes.

3Forward Guidance and Outlook

Growth Expectations: Tempus anticipates sustained growth in the Genomics business at around 25% for the next three years, despite a potential moderation in Hereditary growth.

Future Data Releases: The company plans to release significant data from ongoing studies in CRC and non-small cell lung cancer in 2026, which could bolster its MRD offerings.

4Bad News, Challenges, or Points of Concern

Market Competition: There are competitive pressures in the MRD testing space, with other labs also reporting strong growth, which could impact Tempus's market share.

Regulatory Risks: The timeline for FDA approvals and the subsequent reimbursement landscape remains uncertain, which could affect future revenue streams.

ASP Stability: Average selling prices (ASPs) in the Hereditary space have been stable but slightly down year-over-year due to renegotiated agreements with larger payers.

5Notable Q&A Insights

Sales Force Efficiency: The CEO highlighted that improvements in the sales force's efficiency contributed significantly to the growth, indicating a recovery from previous disruptions caused by restructuring.

Long-term Vision: Management emphasized a commitment to long-term growth rather than short-term gains, aiming for consistent performance rather than reacting to quarterly fluctuations.

Foundation Model Development: Progress on the foundation model with AstraZeneca is on track, with expectations for initial versions to be available in early 2026, indicating a strong focus on AI and data integration in future offerings. Overall, Tempus AI demonstrated robust growth in Q3 2025, achieving key financial milestones while navigating competitive and regulatory challenges. The company remains optimistic about its long-term growth trajectory and strategic initiatives.